Armata Pharmaceuticals (ARMP) Investor presentation summary

Phage therapy advantages and clinical need

• Phage therapy offers a novel approach to combat antimicrobial resistance, with activity independent of antibiotic resistance and potential for monotherapy or combination with antibiotics.

• Species-specific targeting reduces microbiome disruption and is supported by decades of historical data.

• There is an urgent need for pivotal trials to establish phage therapy as an alternative or adjunct to antibiotics, demonstrating non-inferiority and safety.

Clinical pipeline and trial results

• Lead programs AP-SA02 (Staphylococcus aureus bacteremia) and AP-PA02 (Pseudomonas aeruginosa respiratory infections) have completed Phase 2a trials, showing strong efficacy and safety.

• AP-SA02 demonstrated a statistically significant improvement in responder rate (88% vs. 58%, p=0.047) and 100% clinical response at later timepoints, with no treatment-related serious adverse events.

• AP-PA02 showed significant reductions in P. aeruginosa density in non-CF bronchiectasis patients, with efficacy observed at multiple timepoints.

Manufacturing and infrastructure

• In-house, state-of-the-art cGMP facility in Los Angeles enables commercial scalability, parallel production, and contract manufacturing opportunities.

• Infrastructure supports efficient late-stage trials and reduces supply chain risks, with anticipated profitable manufacturing agreements from 2026 onward.